1. Home
  2. BOWN vs TLSA Comparison

BOWN vs TLSA Comparison

Compare BOWN & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOWN
  • TLSA
  • Stock Information
  • Founded
  • BOWN 2023
  • TLSA 2013
  • Country
  • BOWN United States
  • TLSA United Kingdom
  • Employees
  • BOWN N/A
  • TLSA N/A
  • Industry
  • BOWN
  • TLSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • BOWN
  • TLSA Health Care
  • Exchange
  • BOWN Nasdaq
  • TLSA Nasdaq
  • Market Cap
  • BOWN 100.3M
  • TLSA 87.8M
  • IPO Year
  • BOWN 2023
  • TLSA 2000
  • Fundamental
  • Price
  • BOWN $10.92
  • TLSA $0.78
  • Analyst Decision
  • BOWN
  • TLSA
  • Analyst Count
  • BOWN 0
  • TLSA 0
  • Target Price
  • BOWN N/A
  • TLSA N/A
  • AVG Volume (30 Days)
  • BOWN 40.2K
  • TLSA 347.9K
  • Earning Date
  • BOWN 01-01-0001
  • TLSA 12-31-2024
  • Dividend Yield
  • BOWN N/A
  • TLSA N/A
  • EPS Growth
  • BOWN N/A
  • TLSA N/A
  • EPS
  • BOWN 0.39
  • TLSA N/A
  • Revenue
  • BOWN N/A
  • TLSA N/A
  • Revenue This Year
  • BOWN N/A
  • TLSA N/A
  • Revenue Next Year
  • BOWN N/A
  • TLSA N/A
  • P/E Ratio
  • BOWN $28.18
  • TLSA N/A
  • Revenue Growth
  • BOWN N/A
  • TLSA N/A
  • 52 Week Low
  • BOWN $10.32
  • TLSA $0.41
  • 52 Week High
  • BOWN $10.98
  • TLSA $1.74
  • Technical
  • Relative Strength Index (RSI)
  • BOWN 53.13
  • TLSA 33.06
  • Support Level
  • BOWN $10.93
  • TLSA $0.73
  • Resistance Level
  • BOWN $10.97
  • TLSA $1.07
  • Average True Range (ATR)
  • BOWN 0.02
  • TLSA 0.09
  • MACD
  • BOWN -0.01
  • TLSA -0.02
  • Stochastic Oscillator
  • BOWN 14.29
  • TLSA 12.86

About BOWN Bowen Acquisition Corp

Bowen Acquisition Corp is a blank check company.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: